Abstract 647P
Background
Colorectal cancer (CRC) results from the combination of genetic alterations and environmental risk factors. Several evidences indicate that the diet may have a role in prevention and progression of CRC, but more research is needed to clarify the heterogeneity of dietary associations with CRC.
Methods
Patient-derived xenografts (PDXs) were generated implanting subcutaneously human CRCs at different staging into immunodeficient mice, and feeding with control normal diet (ND) and classical western diet (WD). Tumor phenotype, transcriptomic, genetic and metabolomic were analyzed.
Results
The response to WD was heterogeneous among all generated PDXs. Only one out of three showed a greater growth in mice fed with WD. Particularly, WD induced transcriptomic perturbations of several genes related to epigenetic regulations and tumor progression, remodeling tumor microenvironment, promoting mucin secretion, mitochondria dysfunction and metabolic reprogramming. Interestingly, the three PDXs responded to the same WD with a distinct metabolomic profile that was validated through the machine learning. With whole exome sequencing, PDXs did not share the same somatic cancer mutations that could play a key role in conditioning response to a specific diet. Consistently, the same heterogeneous response to WD in tumor growth was observed in xenografts generated with CRC cell lines. To strictly mimics human diet, we tested in comparison to classic WD, humanized WD diet that displayed a different tumor behavior. The analysis of patient derived organoids developed from PDX fed with humanized diets revealed that the altered metabolic reprogramming acquired in vivo is also maintained in vitro in absence of any stimulus, suggesting a metabolic memory of cancer cells.
Conclusions
Specific CRC somatic mutations, modifying several signaling pathway and tumor metabolism promote tumor growth and progression, and could be predictive of a response to a specific diet. In this scenario, PDX could be considered as a suitable approach to study the response to the diet and to provide a screening of different diets in order to create a dietary guidance for CRC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Humanitas University.
Funding
PRIN.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11